Keystone Heart is focused on protecting the brain from emboli to reduce the risk of brain infarcts during TAVR.
Latest News
Share this

Author: Keystone Heart

CRT 2017

February 18-21, 2017     CRT 2017 is one of world’s leading interventional cardiology conferences and is being held in Washington, DC from February 18–21, 2017 at the Omni Shoreham Hotel. Stemming from a long history of success, this year’s CRT conference is destined to be the most...

JIM 2017

February 9-11, 2017   Keystone Heart Ltd. is excited to be participating in JIM 2017 in Milan, Italy February 9th – 11th. The main focus of this event is to have the opportunity to be informed about the very latest Innovation on Interventional Cardiology and to approach...

Delirium Significantly Associated with Brain Lesions in Patients Post-TAVR According to New Data Released at TCT 2016

According to New Data Released at TCT 2016 Delirium Significantly Associated with Brain Lesions in Patients Post-TAVR CAESAREA, Israel, and TAMPA, Florida --November 1, 2016 — Keystone Heart Ltd., an emerging medical device company focused on developing cerebral embolic protection devices for patients undergoing cardiac procedures, today...

American Journal of Cardiology Reports Data Showing New Brain Lesions in 94% of Patients Following TAVR

Data Supports Potential Need for TriGuard™ Cerebral Embolic Protection device being developed by Keystone Heart American Journal of Cardiology Reports Data Showing New Brain Lesions in 94% of Patients Following TAVR CAESAREA, Israel & TAMPA, Fla.--September 30, 2016 — Keystone Heart Ltd., an emerging medical device company focused...

TriGuard Cerebral Protection Device Demonstrates Safety and Significant Improvements in Brain Protection in Patients Undergoing TAVR Procedures

New data presented at PCR London Valves conference TriGuard Cerebral Protection Device Demonstrates Safety and Significant Improvements in Brain Protection in Patients Undergoing TAVR Procedures CAESAREA, Israel & TAMPA, Fla.--September 19, 2016 — Keystone Heart Ltd., an emerging medical device company focused on developing cerebral protection devices for...

Keystone Heart Ltd. Announces First Patient Enrolled in New Study to Protect the Brain During TAVR

Supporting data to be presented at Transcatheter Valve Therapies (TVT) Conference Keystone Heart Ltd. Announces First Patient Enrolled in New Study to Protect the Brain During TAVR CAESAREA, Israel & TAMPA, Fla.--(BUSINESS WIRE)--Keystone Heart Ltd., an emerging medical device company focused on developing cerebral protection devices for patients...

TriGuard Cerebral Protection Device Shows Reduction in Stroke Rate and Improvement in Patients’ Neurological Outcomes in TAVR Procedures

Benefits of Keystone Heart’s TriGuard neuroprotection during TAVR in reducing stroke, CNS infarction and infarction size are supported by results from pooled analysis presented at EuroPCR 2016 TriGuard Cerebral Protection Device Shows Reduction in Stroke Rate and Improvement in Patients’ Neurological Outcomes in TAVR Procedures Benefits of...